Sonoma Pharmaceuticals (SNOA) EBITDA (2010 - 2026)
Sonoma Pharmaceuticals' (SNOA) quarterly EBITDA came in at -$351000.0 in Q1 2026, up 46.49% year-on-year from -$239600.4 in Q1 2025, and up 48.23% quarter-over-quarter from -$678000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) EBITDA (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' EBITDA history runs 17 years deep, the most recent figure standing at -$351000.0 for Q1 2026.
- On a quarterly basis, EBITDA rose 46.49% year-over-year to -$351000.0 in Q1 2026; TTM through Mar 2026 was -$2.5 million, a 33.67% increase from a year earlier, with the FY2026 full-year figure at -$2.5 million, up 33.67% from the prior year.
- EBITDA climbed to -$351000.0 in Q1 2026 per SNOA's latest filing, from -$678000.0 in the prior quarter.
- Across five years, EBITDA topped out at -$337000.0 in Q3 2025 and bottomed at -$3.1 million in Q1 2022.
- The 5-year median for EBITDA is -$1.0 million (2024), against an average of -$1.1 million.
- Across the five-year window, EBITDA plunged 91.44% in 2022 and soared 62.52% in 2023, its largest moves.
- Year by year, EBITDA stood at -$1.8 million in 2022, then jumped by 53.98% to -$844000.0 in 2023, then decreased by 22.16% to -$1.0 million in 2024, then jumped by 34.24% to -$678000.0 in 2025, then jumped by 48.23% to -$351000.0 in 2026.
- Per Business Quant, the three latest SNOA EBITDA figures stand at -$351000.0 (Q1 2026), -$678000.0 (Q4 2025), and -$337000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 325.80 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 291.00 Mn |
| 10 | Sonoma Pharmaceuticals | 179.80 | -2.40 Mn | 2.18 Mn | -351,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -351,000.00 |
| Dec 31, 2025 | -678,000.00 |
| Sep 30, 2025 | -337,000.00 |
| Jun 30, 2025 | -1.10 Mn |
| Mar 31, 2025 | -656,000.00 |
| Dec 31, 2024 | -1.03 Mn |
| Sep 30, 2024 | -850,000.00 |
| Jun 30, 2024 | -1.17 Mn |
| Mar 31, 2024 | -1.41 Mn |
| Dec 31, 2023 | -844,000.00 |
| Sep 30, 2023 | -1.21 Mn |
| Jun 30, 2023 | -1.24 Mn |
| Mar 31, 2023 | -1.15 Mn |
| Dec 31, 2022 | -1.83 Mn |
| Sep 30, 2022 | -731,000.00 |
| Jun 30, 2022 | -855,000.00 |
| Mar 31, 2022 | -3.06 Mn |
| Dec 31, 2021 | -958,000.00 |
| Sep 30, 2021 | -964,000.00 |
| Jun 30, 2021 | -904,000.00 |